APTOCROM Inc. Share Price

A109960

KR7109960005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 28/07/2026			5-day change	1st Jan Change
1,598.00 ^KRW	-1.78%		-5.72%	-68.04%

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	₩1,598.00	-1.78%	6,116
27/07/26	₩1,627.00	-0.97%	7,212
24/07/26	₩1,643.00	+1.17%	2,952
23/07/26	₩1,624.00	-0.79%	5,611
22/07/26	₩1,637.00	-2.56%	27,531

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
A109960 Stock

As early as today, start finding the best investment opportunities!

Market Cap	17.64B 12.01M 10.56M 9.83M 9.03M 16.95M 1.15B 17.17M 117M 45.63M 569M 45.09M 44.12M 1.97B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	446M 304K 267K 249K 228K 429K 29.13M 434K 2.95M 1.15M 14.38M 1.14M 1.12M 49.71M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-15	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/08/25	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
24/06/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
21/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	-1.78%
1 week	-5.72%
Current month	-8.48%
1 month	-5.56%
3 months	-50.37%
6 months	-69.15%
Current year	-68.04%

1 week	1,571	1,678
1 month	1,571	1,790
Current year	1,571	5,400
1 year	1,571	11,820
3 years	1,571	49,900
5 years	1,571	113,000
10 years	1,571	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	22/03/2022
Jong-Su Kang SAM	Sales & Marketing	62	-
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-

APTOCROM Inc. Share Price

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	22/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	09/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	-1.78%	-5.72%	-75.71%	-93.87%	12.23M
ELI LILLY AND COMPANY	+2.16%	+4.39%	+51.83%	+167.62%	1,068B
JOHNSON & JOHNSON	+2.15%	+8.50%	+63.58%	+55.83%	641B
ABBVIE INC.	+3.17%	+3.24%	+40.25%	+75.27%	454B
ROCHE HOLDING AG	+1.93%	+9.92%	+40.79%	+36.19%	351B
NOVARTIS AG	+1.51%	+3.94%	+39.79%	+44.58%	299B
ASTRAZENECA PLC	+0.61%	+4.05%	+20.46%	+17.54%	266B
NOVO NORDISK A/S	+2.73%	+3.44%	-25.70%	-36.56%	220B
AMGEN INC.	+4.57%	+7.17%	+30.27%	+66.06%	203B
GILEAD SCIENCES, INC.	+2.86%	+3.20%	+18.95%	+74.92%	162B
Average	+2.06%	+2.24%	+20.45%	+40.76%	366.34B
Weighted average by Cap.	+2.40%	+2.85%	+40.83%	+81.11%

	2024	2025
Net sales	16.4B 11.17M 9.82M 9.14M 8.39M 15.76M 1.07B 15.97M 109M 42.43M 529M 41.93M 41.02M 1.83B	9.81B 6.68M 5.87M 5.47M 5.02M 9.43M 641M 9.55M 64.97M 25.37M 316M 25.07M 24.53M 1.09B
Net income	-28.09B -19.13M -16.82M -15.66M -14.38M -27M -1.83B -27.36M -186M -72.68M -906M -71.82M -70.27M -3.13B	-5.56B -3.79M -3.33M -3.1M -2.85M -5.34M -363M -5.41M -36.83M -14.38M -179M -14.21M -13.91M -620M
Net Debt	-25.07B -17.07M -15.01M -13.97M -12.83M -24.09M -1.64B -24.41M -166M -64.85M -808M -64.08M -62.7M -2.79B	-17.19B -11.71M -10.29M -9.58M -8.8M -16.52M -1.12B -16.74M -114M -44.48M -554M -43.95M -43M -1.92B